Antharis engages in the discovery and development of monoclonal antibodies (mAbs) and antibody-drug conjugates as next-generation treatments for unmet medical needs in oncology and neurological disorders.

Biological therapeutics can be more effective, specific, stable and safer to patients relative to traditional medications; as such, they are rapidly revolutionizing multiple areas of medicine.

Antharis’ stance in creating the next generation of therapies is unique in at least three ways:

We use unbiased, large-scale screening methods to identify therapeutic targets that are causally relevant to our of interest

By avoiding biases, or a priori knowledge, regarding the cellular mechanisms underlying disease, we rely on biology to instruct us on the most relevant targets for antibody-based therapies.

Biology reveals the best therapeutic targets

We use unbiased, large-scale screening methods to identify therapeutic targets that are causally relevant to our of interest. By avoiding biases, or a priori knowledge, regarding the cellular mechanisms underlying disease, we rely on biology

Biology reveals the best therapeutic targets

We use unbiased, large-scale screening methods to identify therapeutic targets that are causally relevant to our of interest. By avoiding biases, or a priori knowledge, regarding the cellular mechanisms underlying disease, we rely on biology

At the core of Antharis’ commitment to developing transformative medicines for patients in need is the powerful combination of innovative antibody development strategies, creative science and cutting-edge technologies. The use of antibodies to harness and unleash the full power of the immune system holds unparalleled potential to treat a wide array of medical conditions for which there are currently no satisfactory treatment alternatives. We trust antibody therapeutics hold tomorrow’s breakthroughs in healthcare.